Crossmark

VP1 molecular evolution of type 2 immunodeficiency-related vaccine-derived polioviruses (iVDPV2) in a patient with primary immunodeficiency disease (PID)

Crossref DOI link: https://doi.org/10.1007/s11262-026-02214-1

Published Online: 2026-02-02

Published Print: 2026-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Nejati, Ahmad

Khodakhah, Farshad

Soheili, Parastoo

Yousefi, Maryam

Mollaei-Kandelous, Yaghoob

Keyvanlou, Maryam

Razaghi, Mohammad

Yaghoubzadeh, Delaram

Zahraei, Seyed Mohsen

Mahmoudi, Sussan

Shahmahmoodi, Shohreh
License Information

Text and Data Mining valid from 2026-02-02

Version of Record valid from 2026-02-02
More Information

Article History

Received: 30 September 2025

Accepted: 22 January 2026

First Online: 2 February 2026

Declarations

:

: The authors declare no competing interests.

: Samples were routinely collected in the scope of AFP surveillance program for poliovirus detection, as part of the WHO and Ministry of Health and Medical Education. Therefore, this study did not require an ethical approval to conduct the research.

: This research did not involve human participants and/or animals out of poliovirus surveillance.

Document is current

Any future updates will be listed below